- Sitagliptin, sold
under the
brand name
Januvia among others, is an anti-diabetic
medication used to
treat type 2 diabetes. In the
United Kingdom it is...
-
antibody used in
cancer immunotherapy that had $14.3
billion in 2020 revenue;
Januvia (sitagliptin), an anti-diabetic
medication used to
treat type 2 diabetes...
- time in 2010 for its work with
Merck & Co. on the
active ingredient in
Januvia. In 2017, the
company entered a
partnership with Tate & Lyle to provide...
-
class are:
Sitagliptin (FDA
approved 2006,
marketed by
Merck & Co. as
Januvia)
Vildagliptin (EU
approved 2007,
marketed in the EU by
Novartis as Galvus)...
- Food and Drug
Administration (FDA)
approved labeling changes stating that
Januvia (sitagliptin),
Janumet (sitagliptin and
metformin hydrochloride), and Janumet...
- team at
Merck received the Prix
Galien USA
award for
their work on
Januvia™. The
Januvia™
project was the
first project at
Merck to be co-led
solely by women...
- DPP-4.
Examples are:
vildagliptin (Galvus) EU
Approved 2008
sitagliptin (
Januvia) FDA
approved Oct 2006
saxagliptin (Onglyza) FDA
Approved July 2009 linagliptin...
-
osteoporosis Merck $1,552.7 $3,049 $3,134.4 $3,191.2 $3,159.7
sitagliptin Januvia Type 2
diabetes Merck $1,397.1 $667.5 $42.9
simvastatin Zocor Reduction...
-
Boehringer Ingelheim Chronic obstructive pulmonary disease Apr-2002 2018-Jul 14
Januvia Sitagliptin 700,941 3.63%
Merck & Co., Inc.
Diabetes mellitus type 2 Dec-1996...
- This list
includes treatments for: Diabetes: Farxiga, Fiasp/NovoLog,
Januvia,
Jardiance Blood diseases: Eliquis, Xarelto,
Imbruvica Heart failure: Entresto...
